The startup develops vaccines and biotherapeutics utilizing novel viral-vector technology platforms to control infectious diseases in animals and treat chronic conditions in pets. By protecting animal health, the company aims to mitigate the risk of zoonotic diseases that can be transmitted to humans.
Funding
$890K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Livestock and companion animals are susceptible to a range of infectious and chronic diseases that can significantly impact animal health, welfare, and economic productivity. Current vaccines often exhibit limitations in efficacy, have high production costs, or are entirely absent for certain diseases, leaving a critical gap in animal health management. The potential for zoonotic transmission from animals to humans further exacerbates the need for effective animal vaccines.
Solution
The Vaccine Group (TVG) develops innovative animal vaccines and biotherapeutics using a recombinant herpesvirus vector platform to address unmet needs in both livestock and companion animal health. TVG's platform allows for rapid development of novel vaccines by enabling the insertion of multiple genes and targeting of both antibody and T-cell immunity. This approach facilitates the creation of cross-protective and mucosal vaccines that can overcome maternal immunity. TVG's vaccines aim to improve animal welfare, enhance livestock production, and mitigate the risk of zoonotic disease transmission. The company partners with commercial animal health companies for the commercialization of its vaccine candidates.
Target Audience
The primary target audience includes livestock producers, companion animal owners, and veterinary professionals seeking advanced solutions for preventing and managing infectious and chronic diseases in animals.
Features
- Recombinant bovine herpesvirus 4 (BoHV-4) vector platform for vaccine and biotherapeutic delivery
- Ability to target both antibody and T cell immunity for comprehensive immune responses
- Capacity for multigene insertion and expression, enabling the development of multivalent vaccines
- Development of cross-protective vaccines effective against multiple strains or variants
- Mucosal vaccine development for enhanced protection at the site of infection
- Vaccine candidates designed to overcome maternal immunity in young animals
- Rapid vaccine development process, from gene target to trial-ready stocks in six months
- Capability to deliver therapeutic proteins for the treatment of chronic diseases in animals